Treatments for Alzheimer disease

Area of Science:

• Neurology and Geriatric Medicine
• Pharmacological Treatments for Neurodegenerative Diseases

Background:

• The aging global population is experiencing a significant rise in Alzheimer disease (AD) incidence and prevalence.
• Clinicians require evidence-based guidance for patient inquiries regarding AD management strategies.
• Various therapeutic agents have been explored for AD prevention and treatment.

Purpose of the Study:

• To review and synthesize current evidence on therapies for Alzheimer disease (AD) treatment and prevention.
• To provide clinicians with an evidence-based summary to answer patient questions about AD management.

Main Methods:

• Systematic review and synthesis of existing clinical trial data and scientific literature on AD therapies.
• Evaluation of evidence strength for various agents including ginkgo biloba, estrogen, statins, NSAIDs, vitamin E, cholinesterase inhibitors, and memantine.

Main Results:

• Insufficient evidence supports ginkgo biloba, estrogen, statins, or nonsteroidal anti-inflammatory drugs (NSAIDs) for AD prevention or treatment.
• Vitamin E shows limited support from a single trial; other antioxidants have mixed data.
• Cholinesterase inhibitors and memantine demonstrate modest efficacy in treating AD symptoms.
• Cholinesterase inhibitors are effective across all AD stages; memantine is beneficial in late-stage disease, alone or combined with cholinesterase inhibitors.
• No single cholinesterase inhibitor has demonstrated superiority over others.

Conclusions:

• Cholinesterase inhibitors and memantine are the primary evidence-based pharmacological treatments for symptomatic Alzheimer disease (AD).
• Current evidence is insufficient to recommend several commonly discussed agents for AD management.
• Further research is needed to clarify the role of antioxidants and establish treatment guidelines for emerging AD therapies.